Grant ID RP210168
Awarded On August 18, 2021
Title Overcoming Myeloma Resistance to Proteasome Inhibitors
Program Academic Research
Award Mechanism High Impact/High Risk
Institution/Organization The Methodist Hospital Research Institute
Principal Investigator/Program Director Qing Yi
Cancer Sites Myeloma
Contracted Amount $250,000*

*Pending contract negotiation

Lay Summary

Multiple myeloma (MM) is a bone cancer characterized by an accumulation of tumor cells in the bone marrow of patients. MM remains incurable despite large numbers of chemotherapy drugs available for patients. The major problem in the failure to cure MM patients is that patients will become resistant to all clinically used MM drugs, including traditional chemotherapeutics and novel agents. Even worse, some patients exhibit initial resistance and thus never respond to chemotherapy drugs, and most, if not all, MM patients who do respond will relapse after treatment and die from the disease. There is a class of chemotherapy drugs, namely proteasome inhibitors such as bortezomib (Btz) or carfilzom...

Read More